TXONE-NETWORKS
TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment.
All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats.
SageOne essentially covers three main pillars:
- CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the security information of various controls.
- Integrated Lifecycle Protection: Centralized management simplifies cybersecurity governance and achieves collaborative defense. As an abstraction layer, SageOne streamlines the contextualization and consolidation of data across various products. It offers a tailored, task-oriented console designed specifically for executives, security personnel, and plant leaders.
- CPS Threat Detection & Response: Properly handling known threats is absolutely crucial. Coping with unknown threats is equally important. SageOne compiles all security insights from multiple solutions and scouts for potential risks in order to enable early caution and response when needed.
To achieve this goal, the platform includes the following key components:
- Threat intelligence means collecting, analysing and applying knowledge about potential and existing threats against a CPS. The TXOne Threat Research department carries out a large number of investigations into vulnerabilities in Industrial Control Systems (ICS) devices and protocols. It analyses malware and ransomware in connection with Operational Technology (OT) threats. This information can also come from a variety of other sources: Publicly available data, industry reports and private sector information.
- Behaviour-based AI analytics engines use artificial intelligence to monitor and analyse the behaviour of users, devices and systems within a CPS. This advanced analytics engine learns the normal behavioural patterns of these entities and can detect unusual activity or anomalies that could indicate a security threat.
- The Compliance Framework provides a structured approach to compliance with relevant safety standards and regulations. It includes policies, procedures and controls to ensure that every system complies with legal requirements, industry standards and security best practices.
- The Data Visualiser is a tool that transforms complex safety data and metrics into an easy-to-understand visual form. Using diagrams, graphs and network maps, security professionals can recognise patterns and trends as well as anomalies more quickly.
- The Ecosystem Integrator helps to seamlessly integrate different tools and technologies. This includes standardising data formats, promoting the interoperability of different systems and creating a coherent security architecture that covers the entire ecosystem. This enables security forces to obtain a standardised overview of the security situation, automate processes and respond more effectively to threats.
SageOne focuses on the analysis of unexpected behaviour and unknown threats. Suspicious events can be identified by comparing endpoint and network telemetry within the OT-native XDR (Extended Detection and Response) engine. The platform thus combines advanced technologies with a user-friendly interface to ensure the protection of critical infrastructures. To achieve reliable CPS attack surface management, SageOne also offers Asset Centric Visibility to provide full visibility of any device on the network. In addition, the analysis of the attack surface is prioritised and recommendations are made.
To enable a rapid response to threats, SageOne can issue early warnings of suspicious behaviour in the network as part of CPS Threat Detection & Response Orchestration using cross-telemetry analysis.
In addition, Integrated Lifecycle Protection protects devices and systems over their entire service life. The centralised management of the security solutions and the unified defence under one roof contribute to this, resulting in high cost efficiency. With SageOne, TXOne Networks emphasises its commitment to the security and reliability of CPS and continuously drives the development of OT security.
Visit TXOne Networks at the Hannover Messe from 22nd to 26th April 2024 at booth B06 in hall 16.
Follow TXOne Networks on the blog, Twitter and LinkedIn.
About TXOne Networks
TXOne Networks provides OT security products that ensure the reliability and security of industrial control systems and operational technology environments through the OT Zero Trust methodology. TXOne Networks works with both leading industrial manufacturers and critical infrastructure operators to develop practical and business-friendly approaches to OT defence. TXOne Networks offers both network and endpoint-based products to secure OT networks and mission-critical devices in real-time and with high security depth. www.txone.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240420367607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
